BLOG: It's been 12 months since we launched our ambitious plan to halve prostate cancer deaths in a decade, and we’ve already taken some huge steps towards our goal. Our chief executive, Angela Culhane, reflects on the progress we’ve made and the exciting work still to come.
We welcome today's reports of a new test by scientists at the University of East Anglia to determine whether a prostate cancer is aggressive or not, but the tell-tale pattern of 45 specific genes hasn't yet been proven to work for all men.
After today's confirmation that mpMRI scans before a biopsy can radically improve the accuracy of prostate cancer diagnosis, figures reveal that just 32% of eligible men currently have access to the procedure because of a shortage of scanners and qualified staff to use them in the NHS.
BLOG: Today's announcement about mpMRI scans before a biopsy is a game-changer for prostate cancer diagnosis. But without Prostate Cancer UK's funding of a pilot project in 2010 thanks to your donations, this ground-breaking research would never have happened, says Dr Ian Le Guillou.
BLOG: We're only 12 months into our ten-year strategy to tame prostate cancer, but that doesn't mean we haven't already made exciting progress. Our resident expert, Dr Ian Le Guillou, gives us his top ten biggest research breakthroughs (in no particular order) from 2016.
A new type of treatment for early-stage prostate cancer, using lasers to target tumours without damaging surrounding tissue, could offer a choice for men to avoid surgery or radiotherapy. But further research is needed to determine which cancers it's most suited to and the long-term side effects.
The Royal College of Surgeons finds 90 per cent of men who had surgery or radiotherapy to cure their prostate cancer on the English NHS rated their care as very good. But Prostate Cancer UK is concerned that over-treatment of men with low-risk localised disease hasn't declined.
A new type of treatment that alternately floods and starves the body of testosterone has shown good early results in men with advanced prostate cancer, according to new findings revealed today.
With the support of the Movember Foundation, we're funding four PhD students in the crucial field of bioinformatics, using big data to help accelerate our understanding and treatment of prostate cancer.
BLOG: While doom-laden reports about chronic underfunding appear daily in the news, the NHS is still committed to transforming cancer treatment in the UK by 2020. So is it all just pie in the sky? Our Policy Manager, Phillip Anderson, doesn't think so, but argues we must get smarter about making our case for investment in prostate cancer if we're going to get the best deal for men.